X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 44.6 29.9 149.0% View Chart
P/BV x 3.8 2.9 130.3% View Chart
Dividend Yield % 0.3 0.9 36.4%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-17
DR. REDDYS LAB
Mar-17
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6223,397 18.3%   
Low Rs4582,560 17.9%   
Sales per share (Unadj.) Rs181.9856.5 21.2%  
Earnings per share (Unadj.) Rs12.978.0 16.5%  
Cash flow per share (Unadj.) Rs29.3139.9 21.0%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.40.7 55.1%  
Book value per share (Unadj.) Rs155.7739.8 21.0%  
Shares outstanding (eoy) m804.51165.74 485.4%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x3.03.5 85.4%   
Avg P/E ratio x42.038.2 109.8%  
P/CF ratio (eoy) x18.421.3 86.5%  
Price / Book Value ratio x3.54.0 86.2%  
Dividend payout %15.525.7 60.6%   
Avg Mkt Cap Rs m434,516493,632 88.0%   
No. of employees `00023.022.7 101.6%   
Total wages/salary Rs m26,33831,068 84.8%   
Avg. sales/employee Rs Th6,349.16,259.0 101.4%   
Avg. wages/employee Rs Th1,143.01,369.8 83.4%   
Avg. net profit/employee Rs Th449.3569.7 78.9%   
INCOME DATA
Net Sales Rs m146,302141,961 103.1%  
Other income Rs m2,2871,715 133.3%   
Total revenues Rs m148,589143,676 103.4%   
Gross profit Rs m24,75824,722 100.1%  
Depreciation Rs m13,22910,266 128.9%   
Interest Rs m1,594634 251.4%   
Profit before tax Rs m12,22215,537 78.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-70349 -20.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7982,965 60.6%   
Profit after tax Rs m10,35412,921 80.1%  
Gross profit margin %16.917.4 97.2%  
Effective tax rate %14.719.1 77.1%   
Net profit margin %7.19.1 77.8%  
BALANCE SHEET DATA
Current assets Rs m87,37096,837 90.2%   
Current liabilities Rs m33,08184,199 39.3%   
Net working cap to sales %37.18.9 416.8%  
Current ratio x2.61.2 229.6%  
Inventory Days Days8773 118.5%  
Debtors Days Days6298 63.8%  
Net fixed assets Rs m111,567102,552 108.8%   
Share capital Rs m1,609829 194.1%   
"Free" reserves Rs m123,645121,792 101.5%   
Net worth Rs m125,254122,621 102.1%   
Long term debt Rs m36,4545,449 669.0%   
Total assets Rs m209,532218,165 96.0%  
Interest coverage x8.725.5 34.0%   
Debt to equity ratio x0.30 654.9%  
Sales to assets ratio x0.70.7 107.3%   
Return on assets %5.76.2 91.8%  
Return on equity %8.310.5 78.5%  
Return on capital %8.512.9 65.9%  
Exports to sales %34.254.6 62.6%   
Imports to sales %8.39.4 89.2%   
Exports (fob) Rs m50,05077,520 64.6%   
Imports (cif) Rs m12,20313,274 91.9%   
Fx inflow Rs m51,06681,670 62.5%   
Fx outflow Rs m17,67826,355 67.1%   
Net fx Rs m33,38855,315 60.4%   
CASH FLOW
From Operations Rs m23,82421,444 111.1%  
From Investments Rs m-13,127-18,404 71.3%  
From Financial Activity Rs m-13,239-3,692 358.6%  
Net Cashflow Rs m-2,478-1,144 216.6%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS